Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

Running, not enrolling · Phase 3

Conditions studied: Advanced Colorectal Cancer, Metastatic Colorectal Cancer

In brief

Study CA239-0006 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation.

Key facts

Study ID

NCT04793958

Run by

Mirati Therapeutics Inc.

People needed

461

Starts

2021-06-24

Expected to finish

2026-07-31

Last updated by the study team

2026-07-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed diagnosis of colorectal carcinoma with KRAS G12C mutation in tumor tissue.
• Prior receipt of 1st line treatment in advanced CRC with a fluoropyrimidine-based chemotherapy regimen containing either oxaliplatin or irinotecan, and radiographically documented progression of disease on or after treatment.

You may not qualify if…

• Prior treatment with a therapy targeting KRAS G12C mutation (e.g., AMG 510).
• Prior treatment with an anti-EGFR antibody (e.g., cetuximab or panitumumab).
• Active brain metastasis

Where it is running

• Local Institution - 010-855-B — Bessemer, Alabama, United States
• Local Institution - 010-855-D — Birmingham, Alabama, United States
• Local Institution - 010-855-A — Birmingham, Alabama, United States
• Local Institution - 010-855-F — Birmingham, Alabama, United States
• Local Institution - 010-855-C — Birmingham, Alabama, United States
• Local Institution - 010-855 — Birmingham, Alabama, United States
• Local Institution - 010-996 — Gilbert, Arizona, United States
• Local Institution - 010-566 — Goodyear, Arizona, United States
• Local Institution - 010-989 — Phoenix, Arizona, United States
• Local Institution - 010-978 — Springdale, Arkansas, United States
• Local Institution - 010-573 — Bakersfield, California, United States
• Local Institution - 010-979C — Chula Vista, California, United States
• Local Institution - 010-980 — Fresno, California, United States
• Local Institution - 010-851 — Fullerton, California, United States
• Local Institution - 010-979A — La Mesa, California, United States
• Local Institution - 010-958A — Los Angeles, California, United States
• Local Institution - 010-958 — Los Angeles, California, United States
• Local Institution - 010-551 — Los Angeles, California, United States
• Local Institution - 010-847 — Newport Beach, California, United States
• Local Institution - 010-563 — Redlands, California, United States
• Local Institution - 010-979B — San Diego, California, United States
• Local Institution - 010-979D — San Diego, California, United States
• Local Institution - 010-979 — San Diego, California, United States
• Local Institution - 010-982 — San Francisco, California, United States
• Local Institution - 010-855-E — Alabaster, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.